Pharmaceutical composition based on Centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers

Abstract

A pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers, including as active ingredients, centella asiatica and sodium acexamate in amounts producing a reciprocal synergistic effect when mixed with at least one adjuvant selected from a healing agent, an antibiotic agent and/or combinations thereof is described.

Claims

1. A pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers, comprising about 10% to 18% by weight of centella asiatica, about 67% to 75% by weight of sodium acexamate, and about 10% to 18% by weight of an antibiotic agent.

2. A pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers according to claim 1, further comprising about 60 U of collagenase.

3. A pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers according to claim 2, wherein the collagenase is clostridiopeptidase A.

4. A pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers according to claim 1, wherein the antibiotic agent is selected from chloramphenicol, sulfathiazole powder, and ciprofloxacin.

5. A pharmaceutical composition based on centella asiatica (Hydrocotyle asiaticaL.) for the treatment of lower limb ulcers according to claim 2, wherein the composition comprises a bout 14% by weight of centella asiatica; about 71% by weight of sodium acexamate; about 14% by weight of chloramphenicol; and about 60 U of collagenase.

6. A pharmaceutical composition based on centella asiatica (Hydrocotyle asiaticaL.) for the treatment of lower limb ulcers according to claim 1 wherein the composition comprises about 14% by weight of centella asiatica; about 71% by weight of sodium acexamate; and about 14% by weight of sulfathiazole powder.

7. A pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers according to claim 1 wherein the composition comprises about 14% by weight of centella asiatica; about 71% by weight of sodium acexamate; and about 14% by weight of ciprofloxacin.

8. A method for treatment of lower limb ulcers comprising administering to a subject in need a medicament comprising a pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.) as claimed in claim 1.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The novel aspects that are regarded as characteristic of this invention will be particularly set forth in the accompanying claims. However, the invention itself, both by its structure and operation, together with further objects and advantages thereof, will be best understood from the following detailed description of a preferred embodiment when read in connection with the accompanying photos, in which:

(2) Photo 1a shows a venous ulcer wound on the left lower limb of a 72-year-old male patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Aug. 25, 2010.

(3) Photo 1b shows the final result of healing of the wound as shown in photo 1a, once the treatment ended with formulation I of the present invention. Treatment end date: Sep. 1, 2010.

(4) Photo 2a shows a venous ulcer wound on the left lower limb of a 79-year-old male patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Nov. 17, 2011.

(5) Photo 2b shows the final result of healing of the wound as shown in photo 2a, once the treatment ended with formulation I of the present invention. Treatment end date: Dec. 21, 2011.

(6) Photo 3a shows a venous ulcer wound on the left lower limb of an 85-year-old male patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Mar. 2, 2009.

(7) Photo 3b shows the final result of healing of the wound as shown in photo 3a, once the treatment ended with formulation I of the present invention. Treatment end date: Dec. 16, 2009.

(8) Photo 4a shows a varicose ulcer wound on the left lower limb of a 58-year-old female patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Nov. 21, 2011.

(9) Photo 4b shows the final result of healing of the wound as shown in photo 4a, once the treatment ended with formulation I of the present invention. Treatment end date: Dec. 29, 2011.

(10) Photo 5a shows an ulcer wound on the right lower limb of a 64-year-old female patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Apr. 14, 2011.

(11) Photo 5b shows the final result of healing of the wound as shown in photo 5a, once the treatment ended with formulation I of the present invention. Treatment end date: Oct. 26, 2011.

(12) Photo 6a shows a varicose ulcer wound on the left lower limb of a 74-year-old female patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Nov. 10, 2010.

(13) Photo 6b shows the final result of healing of the wound as shown in photo 6a, once the treatment ended with formulation I of the present invention. Treatment end date: Jul. 26, 2011.

(14) Photo 7a shows a varicose ulcer wound on the right lower limb of a 73-year-old female patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Apr. 14, 2011.

(15) Photo 7b shows the final result of healing of the wound as shown in photo 7a, once the treatment ended with formulation I of the present invention. Treatment end date: Jul. 13, 2011.

(16) Photo 8a shows an ulcer wound on the right lower limb of a 55-year-old female patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: May 24, 2010.

(17) Photo 8b shows the final result of healing of the wound as shown in photo 8a, once the treatment ended with formulation I of the present invention. Treatment end date: Jul. 15, 2010.

(18) Photo 9a shows a wound on the right diabetic foot of a 62-year-old male patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Aug. 3, 2011.

(19) Photo 9b shows the final result of healing of the wound as shown in photo 9a, once the treatment ended with formulation I of the present invention. Treatment end date: Nov. 3, 2011.

(20) Photo 10a shows a wound on the right diabetic foot of a 60-year-old male patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: May 26, 2011.

(21) Photo 10b shows the final result of healing of the wound as shown in photo 10a, once the treatment ended with formulation I of the present invention. Treatment end date: Jul. 19, 2011.

(22) Photo 11a shows a wound on the left diabetic foot of a 67-year-old female patient, prior to undergoing the treatment with formulation I of the present invention. Treatment start date: Jan. 30, 2012.

(23) Photo 11b shows the final result of healing of the wound as shown in photo 11a, once the treatment ended with formulation I of the present invention. Treatment end date: Mar. 27, 2012.

(24) Photo 12a shows a highly complex wound on the right leg of a 32-year-old male patient, prior to undergoing the treatment with formulation II of the present invention. Treatment start date: Feb. 16, 2009.

(25) Photo 12b shows the final result of healing of the wound as shown in photo 12a, once the treatment ended with formulation II of the present invention. Treatment end date: Aug. 6, 2009.

(26) Photo 13a shows a trophic ulcer wound on the right foot of a 57-year-old female patient, prior to undergoing the treatment with formulation II of the present invention. Treatment start date: Oct. 29, 2007.

(27) Photo 13b shows the final result of healing of the wound as shown in photo 13a, once the treatment ended with formulation II of the present invention. Treatment end date: Jan. 31, 2008.

(28) Photo 14a shows a varicose ulcer wound on the left lower limb of a 58-year-old female patient, prior to undergoing the treatment with formulation II of the present invention. Treatment start date: May 16, 2011.

(29) Photo 14b shows the final result of healing of the wound as shown in photo 14a, once the treatment ended with formulation II of the present invention. Treatment end date: Jul. 11, 2011.

(30) Photo 15a shows a varicose ulcer wound on the right lower limb of a 60-year-old male patient, prior to undergoing the treatment with formulation II of the present invention. Treatment start date: May 20, 2010.

(31) Photo 15b shows the final result of healing of the wound as shown in photo 15a, once the treatment ended with formulation II of the present invention. Treatment end date: Dec. 27, 2010.

(32) Photo 16a shows an ulcer wound on the left lower limb of a 65-year-old female patient, prior to undergoing the treatment with formulation II of the present invention. Treatment start date: May 13, 2009.

(33) Photo 16b shows the final result of healing of the wound as shown in photo 16a, once the treatment ended with formulation II of the present invention. Treatment end date: Nov. 30, 2009.

(34) Photo 17a shows a highly complex wound on the left leg of an 82-year-old female patient, prior to undergoing the treatment with formulation II of the present invention. Treatment start date: Oct. 12, 2005.

(35) Photo 17b shows the final result of healing of the wound as shown in photo 17a, once the treatment ended with formulation II of the present invention. Treatment end date: Mar. 2, 2006.

(36) Photo 18a shows a varicose ulcer wound on the right lower limb of a 62-year-old female patient, prior to undergoing the treatment with formulation II of the present invention. Treatment start date: Jun. 18, 2007.

(37) Photo 18b shows the final result of healing of the wound as shown in photo 18a, once the treatment ended with formulation II of the present invention. Treatment end date: Jul. 16, 2008.

(38) Photo 19a shows a venous ulcer wound on the right lower limb of a 76-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Oct. 5, 2011.

(39) Photo 19b shows the final result of healing of the wound as shown in photo 19a, once the treatment ended with formulation III of the present invention. Treatment end date: Feb. 8, 2012.

(40) Photo 20a shows an ulcer wound on the left lower limb of a 36-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Oct. 20, 2011.

(41) Photo 20b shows the final result of healing of the wound as shown in photo 20a, once the treatment ended with formulation III of the present invention. Treatment end date: Feb. 1, 2012.

(42) Photo 21a shows an ulcer wound on the right lower limb of a 57-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Jul. 22, 2010.

(43) Photo 21 b shows the final result of healing of the wound as shown in photo 21a, once the treatment ended with formulation III of the present invention. Treatment end date: Apr. 28, 2011.

(44) Photo 22a shows a venous ulcer wound on the right lower limb of a 77-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Oct. 17, 2011.

(45) Photo 22b shows the final result of healing of the wound as shown in photo 22a, once the treatment ended with formulation III of the present invention. Treatment end date: Dec. 26, 2011.

(46) Photo 23a shows a wound on the left diabetic foot of a 54-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Apr. 28, 2011.

(47) Photo 23b shows the final result of healing of the wound as shown in photo 23a, once the treatment ended with formulation III of the present invention. Treatment end date: Jun. 1, 2011.

(48) Photo 24a shows an ulcer wound on the left lower limb of a 67-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Jun. 2, 2010.

(49) Photo 24b shows the final result of healing of the wound as shown in photo 24a, once the treatment ended with formulation III of the present invention. Treatment end date: Aug. 11, 2010.

(50) Photo 25a shows an ulcer wound on the right buttock of a 65-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Aug. 25, 2011.

(51) Photo 25b shows the final result of healing of the wound as shown in photo 25a, once the treatment ended with formulation III of the present invention. Treatment end date: Feb. 28, 2010.

(52) Photo 26a shows a varicose ulcer wound on the right lower limb of a 57-year-old female patient, prior to undergoing the treatment with formulation III of the present invention. Treatment start date: Apr. 26, 2010.

(53) Photo 26b shows the final result of healing of the wound as shown in photo 26a, once the treatment ended with formulation III of the present invention. Treatment end date: Aug. 5, 2010.

BRIEF DESCRIPTION OF THE INVENTION

(54) Compositions of the present invention are preferably used for the treatment of lower limb ulcers, and contain centella asiatica and sodium acexamate as active ingredients.

(55) In a preferred embodiment of the present invention, the composition comprises from about 10% to 18% of centella asiatica; from about 67% to 75% of sodium acexamate; from about 10% to 18% of chloramphenicol; and about 60 U of collagenase (clostridiopeptidase A).

(56) In a particularly preferred embodiment of the composition used in the present invention, said composition comprises about 14% of centella asiatica; about 71% of sodium acexamate; about 14% of chloramphenicol; and 60 U of collagenase (clostridiopeptidase A).

(57) In another preferred embodiment of the present invention, the composition comprises from about 10% to 18% of centella asiatica; from about 67% to 75% of sodium acexamate; and from about 10% to 18% of sulfathiazole powder.

(58) In a particularly preferred embodiment of the composition used in the present invention, said composition comprises about 14% of centella asiatica; about 71% of sodium acexamate; and about 14% of sulfathiazole powder.

(59) In a further embodiment of the present invention, the composition comprises from about 10% to 18% of centella asiatica; from about 67% to 75% of sodium acexamate; and from about 10% to 18% of ciprofloxacin.

(60) In a particularly preferred embodiment of the composition used in the present invention, said composition comprises about 14% of centella asiatica; about 71% of sodium acexamate; and about 14% of ciprofloxacin.

DETAILED DESCRIPTION OF THE INVENTION

(61) The present invention relates to a pharmaceutical composition based on centella asiatica (Hydrocotyle asiatica L.), in combination with sodium acexamate for the treatment of lower limb ulcers.

(62) In accordance with one of the aspects of the invention, a medicament in the form of an ointment, cream, gel or the like for topical application to the patient's skin for the treatment of lower limb ulcers, comprising centella asiatica (Hydrocotyle asiatica L.) and sodium acexamate, supplemented by one or more adjuvants is provided.

(63) The treatment of ulcers essentially consists of a topical administration of a mixture of compounds comprising centella asiatica (Hydrocotyle asiatica L.) and sodium acexamate as active ingredients.

(64) Among the supplements used as adjuvants to enhance the therapeutic effect of the mixture of the present invention are the following compounds: healing agents such as collagenase (clostridiopeptidase A); and antibiotic agents such as chloramphenicol, sulfathiazole, and ciprofloxacin or any other antibiotic agent as required, depending on the infection to be treated.

(65) The compound commonly known as centella asiatica (Hydrocotyle asiatica L.), is a magnolophyta phanerogam plant of the genus Centella in the Apiaceae family, also known as Gotu Kola, Antanan, Pegaga, and Brahmi.

(66) Centella asiatica as such has great properties in both cosmetic and therapeutic aspects. One of the first properties discovered for this plant, was its high and fast tissue healing and repairing power, which is an exceptional property for treating wounds, burns, skin sores, acne, etc.

(67) Besides stimulating collagen formation, centella asiatica has healing and calming effects because of its nature. It is known that if the plant is placed as a poultice over wounds, it turns out to be a very effective remedy that helps healing.

(68) Meanwhile, sodium acexamate, also known as 6-acetylaminocaproic acid, acexamic acid, 6-acetamidohexanoic acid, or 6-(acetylamino)hexanoic acid, has a Molecular Weight of 173.2096 g/mol and the Molecular Formula C.sub.8H.sub.15NO.sub.3.

(69) Sodium acexamate is a compound which mechanism of action is involved in the protein action of the collagen, enabling it to act in the healing process by regulating the production of fibroblasts and arrangement of collagenous fibers.

(70) It shows poor absorption by cutaneous administration, remaining almost unchanged at the site of application, a property that is exploited to achieve a therapeutic effect at the site of injury. Also, by salifying it with sodium a higher absorption is obtained at a local tissue level.

(71) Sodium acexamate also has an antiseptic effect that stimulates the fibroblast action to form fibers, thus contributing to the formation of the dermal matrix.

(72) Meanwhile, collagenase is a zinc-containing enzyme that cleaves peptide bonds of type (I, II, III, IV, V) collagens. Collagenase belongs to a family of enzymes from various cellular sources and specificities for different substrates. Besides degrading collagen such as MMP (matrix metalloproteinase), these enzymes inactivate AAT (alpha-1-antitrypsin) and activate TNF-alpha (Tumor Necrosis Factor alpha).

(73) Collagenase mainly acts on connective tissue in muscle cells and on some other parts of the body.

(74) Medicinal collagenase (clostridiopeptidase A) is an enzyme that is extracted from a clostridium growth medium and is used to remove cellular and extracellular debris from necrotic tissue.

(75) It has been approved as a medicament for use as a healing agent, so it is generally used in ulcers, bedsores, burns and injuries, as it helps in the formation of new tissue and re-epithelialization of skin ulcers and bedsores. Collagen of healthy or newly formed tissue was found not to be attacked by collagenase.

(76) Chloramphenicol is a broad-spectrum antibiotic which was obtained for the first time from soil bacteria of the family of Actinomycetales, Streptomyces venezuelae and is currently produced by synthesis.

(77) Chloramphenicol is thermally stable, effective against a wide range of microorganisms, particularly staphylococci, but due to its serious side effects (damage to the bone marrow, including aplastic anemia) in humans its use is limited to very serious infections such as typhoid fiber.

(78) Sulfathiazole is a sulphonamide for external use, used as a healing and anti-infective agent which has the molecular formula C.sub.9H.sub.9N.sub.3O.sub.2S.sub.2.

(79) Sulfamides are poorly soluble in water so that when used in a powder form increase the residence time on wounds.

(80) It is a white crystalline powder having antiseptic and healing action, which within its antiseptic action, antibacterial action is highlighted. It is used on wounds to prevent infections and promote healing, besides being used in other preparations as antiseptic active ingredient.

(81) Ciprofloxacin is a broad-spectrum antibiotic of the fluoroquinolone group having bactericidal effects.

(82) It is active against Gram-positive and Gram-negative bacteria. It works by inhibiting DNA gyrase, type II topoisomerasa, which is an enzyme needed to cleave replicated DNA, inhibiting cell division. It is effective against Enterobacteriaceae, Vibrio, Haemophilus influenzae, Haemophilus ducreyi, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella catarrhalis, Brucella, Campylobacter, Mycobacterium intracellulare, Legionella sp., Pseudomonas aeruginosa, Bacillus anthracis. In cell culture, it is used to treat mycoplasma infections.

(83) The compounds centella asiatica and sodium acexamate which are employed for the manufacture of a medicament used in the treatment of lower limb ulcers, namely, diabetic foot and traumatic and/or surgical wounds of the lower limbs, are preferably applied in the form of mixtures in combination with adjuvants, particularly forming appropriate mixtures being employed for topical administration of medicaments.

(84) Mixtures of the present invention may take a wide variety of forms, preferably taking the form of an ointment or salve.

(85) The ointment of the present invention, used for the treatment of lower limb ulcers such as those present in the diabetic foot, comprises the centella asiatica and sodium acexamate active ingredients, and at least one adjuvant. The centella asiatica used is in the form of an ointment and powders, and sodium acexamate is found in the form of a cream and/or ointment.

(86) Medicaments of the present invention, due to their activity spectrum, allow both the diabetic foot and varicose ulcer caused by Gram-positive bacteria, Gram-negative bacteria, and anaerobic bacteria to be treated.

(87) In another aspect, the present invention relates to compositions comprising centella asiatica and sodium acexamate in amounts producing a reciprocal synergistic effect when mixed with at least one adjuvant selected from a healing agent, an antibiotic agent and/or combinations thereof.

(88) Compositions of the present invention are preferably used for the treatment of lower limb ulcers, and contain centella asiatica and sodium acexamate as active ingredients.

(89) In a preferred embodiment of the present invention, the composition comprises from about 10% to 18% of centella asiatica; from about 67% to 75% of sodium acexamate; from about 10% to 18% of chloramphenicol; and about 60 U (Units of Enzyme Activity) of collagenase (clostridiopeptidase A).

(90) In a particularly preferred embodiment of the composition used in the present invention, said composition comprises about 14% of centella asiatica; about 71% of sodium acexamate; about 14% of chloramphenicol; and 60 U of collagenase (clostridiopeptidase A).

(91) In another preferred embodiment of the present invention, the composition comprises from about 10% to 18% of centella asiatica; from about 67% to 75% of sodium acexamate; and from about 10% to 18% of sulfathiazole powder.

(92) In a particularly preferred embodiment of the composition used in the present invention, said composition comprises about 14% of centella asiatica; about 71% of sodium acexamate; and about 14% of sulfathiazole powder.

(93) In a further embodiment of the present invention, the composition comprises from about 10% to 18% of centella asiatica; from about 67% to 75% of sodium acexamate; and from about 10% to 18% of ciprofloxacin.

(94) In a particularly preferred embodiment of the composition used in the present invention, said composition comprises about 14% of centella asiatica; about 71% of sodium acexamate; and about 14% of ciprofloxacin.

(95) The ointment or salve for the treatment of lower limb ulcers can be prepared following methods generally employed in techniques for preparing pharmaceutical formulations having this presentation, namely, manual mixing by mortar, to finally obtain the ointment or salve through the obtained mixtures.

(96) The following examples are intended to illustrate and not limit the scope of the present invention in all its aspects.

Composition Examples

(97) Three pharmaceutical formulations in the form of an ointment are prepared, which contain:

(98) Formulation I

(99) TABLE-US-00001 Standardized extract from dried leaves of centella asiatica 1000 mg. Sodium acexamate 5000 mg. Collagenase (clostridiopeptidase A) 60 U. Chloramphenicol 1000 mg.

(100) Formulation II

(101) TABLE-US-00002 Standardized extract from dried leaves of centella asiatica 1000 mg. Sodium acexamate 5000 mg. Sulfathiazole powder 1000 mg.

(102) Formulation III

(103) TABLE-US-00003 Standardized extract from dried leaves of centella asiatica 1000 mg. Sodium acexamate 5000 mg. Ciprofloxacin 1000 mg.

(104) The ointment preparation includes the step of mixing each formulation with the active ingredient.

Pharmacological Examples

(105) A prospective open study in 26 patients between the age of 32 and 85 years with clinical symptoms of lower limb ulcers of different severity degrees was performed.

(106) Patients received a treatment that consists of applying an ointment prepared with each of the Formulations I, II or III, prior asepsis of the ulcer or wound, the formulation was applied as required for each particular case based on the medical diagnosis. The ulcer with applied ointment was covered with a dressing and then covered with a bandage. The treatment was repeated every 3, 5 or 7 days, depending on each particular case. After ending the treatment, all patients exhibited 100% healing, so that it is considered to be a complete cure.

(107) No side effects from the administration of this treatment scheme in patients were observed.

(108) Results

(109) Formulation I

(110) 1).A 72-year-old hypertensive male with venous ulcer on the left lower limb began the treatment on Aug. 25, 2010 and was discharged on Sep. 1, 2010.

(111) 2).A 79-year-old male with venous ulcer on the left lower limb began the treatment on Nov. 17, 2011 and was discharged on Dec. 21, 2011.

(112) 3).An 85-year-old hypertensive, diabetic male with venous ulcer on the left lower limb began the treatment on Mar. 2, 2009 and was discharged on Dec. 16, 2009.

(113) 4).A 58-year-old hypertensive female with varicose ulcer on the left lower limb began the treatment on Nov. 21, 2011 and was discharged on Dec. 29, 2011.

(114) 5).A 64-year-old hypertensive female with ulcer on right lower limb began the treatment on Apr. 14, 2011 and was discharged on Oct. 26, 2011.

(115) 6).A 74-year-old female with varicose ulcer on the left lower limb began the treatment on Nov. 10, 2010 and was discharged on Jul. 26, 2011.

(116) 7).A 73-year-old hypertensive, diabetic female with varicose ulcer on the right lower limb began the treatment on Apr. 14, 2011 and was discharged on Jul. 13, 2011.

(117) 8).A 55-year-old hypertensive female with ulcer on the right lower limb began the treatment on May 24, 2010 and was discharged on Jul. 15, 2010.

(118) 9).A 62-year-old diabetic male with a right diabetic foot began the treatment on Aug. 3, 2011 and was discharged on Nov. 3, 2011.

(119) 10).A 60-year-old diabetic and hypertensive male with a right diabetic foot began the treatment on May 26, 2011 and was discharged on Jul. 19, 2011.

(120) 11).A 67-year-old diabetic female with a left diabetic foot began the treatment on Jan. 30, 2012 and was discharged on Mar. 27, 2012.

(121) Formulation II

(122) 1).A 32-year-old diabetic male with a right foot complex began the treatment on Feb. 16, 2009 and was discharged on Aug. 6, 2009.

(123) 2).A 57-year-old hypertensive, diabetic female with trophic ulcer on the right foot began the treatment on Oct. 29, 2007 and was discharged on Jan. 31, 2008.

(124) 3).A 58-year-old female with varicose ulcer on the left lower limb began the treatment on May 16, 2011 and was discharged on Jul. 11, 2011.

(125) 4).A 60-year-old male with varicose ulcer on the right lower limb began the treatment on May 20, 2010 and was discharged on Dec. 27, 2010.

(126) 5).A 65-year-old female with ulcer on the left lower limb began the treatment on May 13, 2009 and was discharged on Nov. 30, 2009.

(127) 6).An 82-year-old female with a left foot complex began the treatment on Oct. 12, 2005 and was discharged on Mar. 2, 2006.

(128) 7).A 62-year-old diabetic female with varicose ulcer on the right lower limb began the treatment on Jun. 18, 2007 and was discharged on Jul. 16, 2008.

(129) Formulation III

(130) 1).A 76-year-old female with venous ulcer on the right lower limb began the treatment on Oct. 5, 2011 and was discharged on Feb. 8, 2012.

(131) 2).A 36-year-old female with ulcer on the left lower limb began the treatment on Oct. 20, 2011 and was discharged on Feb. 1, 2012.

(132) 3).A 57-year-old diabetic female with ulcer on the right lower limb began the treatment on Jul. 22, 2010 and was discharged on Apr. 28, 2011.

(133) 4).A 74-year-old hypertensive female with venous ulcer on the right lower limb began the treatment on Oct. 17, 2011 and was discharged on Dec. 26, 2011.

(134) 5).A 54-year-old diabetic female with diabetic foot began the treatment on Apr. 28, 2011 and was discharged on Jun. 1, 2011.

(135) 6).A 67-year-old female with ulcer on the left lower limb began the treatment on Jun. 2, 2010 and was discharged on Aug. 11, 2010.

(136) 7).A 65-year-old hypertensive female with ulcer on the right buttock began the treatment on Aug. 25, 2011 and was discharged on Feb. 28, 2012.

(137) 8).A 57-year-old diabetic and hypertensive female with varicose ulcer on the left lower limb began the treatment on Apr. 26, 2010 and was discharged on Aug. 5, 2010.

(138) As can be seen from the examples, upon ending the treatments all patients exhibited 100% healing so that it is considered to be a complete cure.

(139) No side effects from the administration of this treatment scheme in patients were observed.

(140) In accordance with the above description, it could be seen that a mixture of the standardized extract from dried leaves of centella asiatica, sodium acexamate, and an antibiotic agent such as chloramphenicol, sulfathiazole powder, ciprofloxacin or any other antibiotic agent, depending on the infection to be treated, surprisingly exhibits a highly effective synergistic effect for healing lower limb ulcers, ensuring a high possibility of therapeutic success.

(141) Although certain embodiments of the invention have been illustrated and described, it should be noted that numerous modifications to them are possible. The present invention, therefore, should not be regarded as restricted, except as required by the prior art and the spirit of the accompanying claims.